Correlation of CYP2B6, CYP2C19, ABCC4 and SOD2 genotype with outcomes in allogeneic blood and marrow transplant patients

John L. Black, Mark R Litzow, William Hogan, Dennis J. O'Kane, Denise L. Walker, Timothy G. Lesnick, Walter K Kremers, Rajeswari Avula, Rhett P. Ketterling

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

CYP2B6, CYP2C19, ABCC4, and SOD2 have been implicated in adverse drug reactions and survival after cyclophosphamide (CPA) treatment. 110 BMT patients who received high dose CPA treatment were genotyped for variants in these genes and the results were correlated with toxicity and relapse. CYP2B6 genotype significantly influenced overall toxicity suggesting active CYP2B6 alleles led to higher rates of overall toxicity. The p.R487C deficiency allele was significantly associated with a lower rate of overall toxicity and a higher rate of relapse. SOD2 rs4880 V16A polymorphism was associated with significantly less CPA-related overall toxicity and significantly lower relapse rates by Kaplan-Meier analysis although the SOD2 finding regarding relapse was not significant when evaluated by the cumulative incidence function.

Original languageEnglish (US)
Pages (from-to)59-66
Number of pages8
JournalLeukemia Research
Volume36
Issue number1
DOIs
StatePublished - Jan 2012

    Fingerprint

Keywords

  • ABCC4
  • Blood or marrow transplantation
  • Cyclophosphamide
  • CYP2B6
  • CYP2C19
  • SOD2

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this